Clinical Trial Update: A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of avelumab, binimetinib, and talazoparib in locally advanced or metastatic RAS-mutant solid tumors was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Avelumab (avelumab)
• Binimetinib (binimetinib)
• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-01-26